Comparative Pharmacology
Head-to-head clinical analysis: ADRENALIN versus EPIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRENALIN versus EPIPEN.
ADRENALIN vs EPIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-1 activation causes vasoconstriction, beta-1 activation increases heart rate and contractility, beta-2 activation causes bronchodilation.
Nonselective alpha-1, alpha-2, beta-1, beta-2, beta-3 adrenergic receptor agonist; causes vasoconstriction (alpha-1), bronchodilation (beta-2), and increased cardiac contractility and heart rate (beta-1).
1 mg (1 mL of 1:1000 solution) intramuscularly or subcutaneously every 5-20 minutes as needed; for cardiac arrest: 1 mg intravenously or intraosseously every 3-5 minutes.
0.3 mg intramuscularly (lateral thigh) every 5-15 minutes as needed for anaphylaxis.
None Documented
None Documented
Approximately 2-3 minutes for the parent drug in plasma; clinical effects are short-lived due to rapid uptake and metabolism. In severe shock or hepatic impairment, half-life may be slightly prolonged.
2-3 minutes (IV); clinical context: ultra-short half-life necessitates repeated doses or continuous infusion for sustained effect
Primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Renal excretion of metabolites (metanephrine, vanillylmandelic acid) and unchanged drug (<2% as unchanged). Biliary/fecal excretion is minimal (<5%).
Renal (90% as metabolites, 10% unchanged); biliary/fecal (<5%)
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist